The FDA-approved Pt(II)-based drugs cisplatin, carboplatin, and oxaliplatin, are mainstays in modern cancer chemotherapy. However, resistance to these agents is generally seen after initial treatments. This resistance often becomes dose-limiting and, in the case of NSCLC treatment, is manifest in a ca. 5% five-year survival rate. One way this resistance could be reduced or overcome would be through targeting the Pt complexes to cancerous lesions. With such a vision in mind, we have created several Gd-Tex Pt conjugates with the goal of improving the delivery and reducing the toxicity issues observed with cisplatin and other Pt(II) based therapeutics. This presentation will provide a summary of efforts along these lines.